Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-28 EDT			5-day change	1st Jan Change
38.61 ^USD	+0.63%		-0.95%	-16.17%

05-28	Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting	CI
05-16	Transcript : Xenon Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM

Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 01, 2023 at 04:40 pm

Xenon Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 9.43 million compared to USD 18.44 million a year ago. Net loss was USD 125.37 million compared to USD 78.88 million a year ago.

Latest news about Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting	05-28	CI
Transcript : Xenon Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM	05-15
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating	05-10	MT
Xenon Pharmaceuticals Q1 Net Loss Narrows	05-09	MT
Transcript : Xenon Pharmaceuticals Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Xenon Pharmaceuticals Inc. Announces Board Resignations	04-19	CI
Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM	03-11
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	03-08	MT
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	03-08	MT
Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating	03-01	MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk	03-01	MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating	03-01	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Xenon Pharmaceuticals Q4 Net Loss Widens	02-29	MT
Transcript : Xenon Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	02-26	CI
Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	02-26	CI
Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	02-26	CI
Transcript : Xenon Pharmaceuticals Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:00 AM	01-08
Citigroup Initiates Xenon Pharmaceuticals With Buy Rating, Price Target is $62	01-04	MT
Stifel Adjusts Price Target on Xenon Pharmaceuticals to $62 From $53, Maintains Buy Rating	12-18	MT
Xenon Pharmaceuticals Insider Sold Shares Worth $758,983, According to a Recent SEC Filing	12-15	MT
Baird Initiates Xenon Pharmaceuticals With Outperform Rating, Price Target is $63	12-08	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	11-30	MT

Chart Xenon Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.61 USD

Average target price

58.22 USD

Spread / Average Target

+50.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENON PHARMACEUTICALS INC.	-16.17%	2.9B
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs